The Indiana University-Ohio State University Maternal and Pediatric Precision in Therapeutics Data, Model, Knowledge, and Research Coordination Center (IU-OSU MPRINT DMKRCC)

项目总结/摘要 早发性或早产儿先兆子痫仅发生在0.5%的妊娠中，但它与长期妊娠的高风险相关。 足月母体并发症，以及胎儿发病率和死亡率高。与早发性乳腺癌相关的生物标志物 需要对先兆子痫进行评估，以确定处于早发性先兆子痫风险中的妇女，指导治疗方案， 并支持开发新的治疗方法来预防和治疗该疾病。此外，重要的是 了解早产儿先兆子痫对母亲和孩子的长期影响。但由于 早发性先兆子痫发病率低，很难从足够的 通过一个中心或研究的女性人数。无论是作为预期的生物库努力或剩余收集 来自临床研究的残留样本，来自母体和儿科患者的大量生物样本 世界各地的仓储设施。这些未开发的生物样本及其相关数据有可能大大提高 加强孕产妇和儿科治疗研究，特别是针对罕见病症和疾病，如早发性 先兆子痫然而，没有单一的资源来确定产妇和儿科生物标本的来源，所以往往 寻找这些样本的翻译研究人员可能不知道它们的存在。该提案将体现 现有的孕产妇和儿科生物标本和调查研究者的情况，以了解 翻译研究社区。我们将开发协作在线围产期和儿科知识库（COPPER）， 一个用户友好的平台，以便于确定生物库和网络与剩余的生物标本， 支持孕产妇和儿科精准治疗研究。通过调查和工作组讨论，我们将寻求 了解与生物标本未来使用有关的法规的演变，并提出加强 将长期儿科结局与围产期采集的样本联系起来的能力。在这个项目结束时， 我们将开发一个集中资源，提供有关生物储存库的信息， 儿科转化研究和精确治疗，制定建议，以提高能力， 和儿童数据和标本，并确定生物标本和相关的临床数据，以支持未来的工作， 生物标志物和治疗方法，以预防和治疗早发性先兆子痫。

Project Summary/Abstract Early-onset, or preterm, preeclampsia occurs in only 0.5% of pregnancies, but it is associated with a high risk of long- term maternal complications, as well as high fetal morbidity and mortality. Biomarkers associated with early-onset preeclampsia are needed to identify women at risk of developing early-onset preeclampsia, guide treatment options, and support development of new therapeutic approaches to prevent and treat the disease. Additionally, it is important to understand the long-term consequences of preterm preeclampsia in both the mother and child. However, due to the low incidence of early-onset preeclampsia, it is difficult to obtain data and necessary biospecimens from a sufficient number of women through a single center or study. Whether collected as a prospective biobanking endeavor or leftover residual samples from clinical studies, numerous biospecimens from maternal and pediatric patients reside within storage facilities across the world. These untapped biosamples and their associated data have the potential to greatly enhance maternal and pediatric therapeutics research, especially for rare conditions and diseases such as early-onset preeclampsia. However, there is no single resource to identify sources of maternal and pediatric biospecimens, so often translational researchers seeking such samples may not be aware of their existence. This proposal will characterize the landscape of available maternal and pediatric biospecimens and survey investigators to understand the needs of the translational research community. We will develop The Collaborative Online Perinatal & PEdiatric Repository (COPPER), a user-friendly platform to facilitate identification of biobanks and networks with residual biospecimens available to support maternal and pediatric precision therapy research. Through surveys and working group discussions, we will seek to understand the evolution of regulations relating to future use of biospecimens and propose strategies to enhance the ability to link long-term pediatric outcomes to samples collected during the perinatal period. At the end of this project, we will develop a centralized resource providing information on biorepositories which could support maternal and pediatric translational research and precision therapeutics, develop proposals to enhance the ability to link maternal and child data and specimens, and identify biospecimens and associated clinical data to support future work to develop biomarkers and therapeutic approaches to prevent and treat early-onset preeclampsia.